Ticker Scorecard - LGND Basics Company: Ligand Pharmaceuticals Incorporated IPO Date: September 7, 2005 Sector: Healthcare Industry: Biotech Market Cap: $2.28B Activated in VL: True Average Daily Range Avg Daily Range: $1.35 | 2.14% Avg Daily Range (30 D): $1.49 | 1.31% Avg Daily Range (90 D): $2.09 | 1.81% Institutional Daily Volume Avg Daily Volume: .2M Avg Daily Volume (30 D): .06M Avg Daily Volume (90 D): .07M Trade Size Avg Trade Size (Sh.): 68 Avg Trade Size (Sh.) (30 D): 29 Avg Trade Size (Sh.) (90 D): 30 Institutional Trades Total Inst.Trades: 5,176 Avg Inst. Trade: $3.11M Avg Inst. Trade (30 D): $1.87M Avg Inst. Trade (90 D): $2.58M Avg Inst. Trade Volume: .03M Avg Inst. Trades (Per Day): 1 Market Closing Trades Avg Closing Trade: $3.21M Avg Closing Trade (30 D): $1.74M Avg Closing Trade (90 D): $2.42M Avg Closing Volume: 30.33K     News Oct 17, 2024 @ 11:30 AM Palvella Therapeutics Appoints Matthew E. Korenber... Source: Globe Newswire Jul 23, 2024 @ 7:16 PM LGND reaches 52-week high, hitting $103.295 - Inve... Source: Investing.Com Jun 28, 2024 @ 7:01 PM What 4 Analyst Ratings Have To Say About Ligand Ph... Source: Benzinga Insights Jun 24, 2024 @ 6:10 PM Bristol Myers' (BMY) Krazati Gets FDA Nod for Colo... Source: Zacks Equity Research Jun 21, 2024 @ 1:17 PM Gilead (GILD) Up as Twice-Yearly HIV Shot Prevents... Source: Zacks Equity Research Financials   TTM Q3 2024 Q2 2024 Basic EPS $2.57 $-.39 $-2.88 Diluted EPS $2.51 $-.39 $-2.88 Revenue $ 152.42M $ 51.81M $ 41.53M Gross Profit $ $ $ Net Income / Loss $ 45.24M $ -7.17M $ -51.91M Operating Income / Loss $ -16.33M $ 3.14M $ -19.1M Cost of Revenue $ $ $ Net Cash Flow $ 43.76M $ 45.48M $ -31.95M PE Ratio 48.08     Splits Nov 19, 2010:   6:1